Widespread use of polypills could prevent up to 72 million heart disease deaths
The use of single-pill combination (SPC) therapies, also known as polypills, could prevent millions of deaths in the years ahead, according to new research published in the Journal of the American College of Cardiology.[1]
“One of the biggest challenges to improving population cardiovascular health is effective implementation, at a significant scale, of simple healthcare-based interventions that have been proven to benefit persons at high risk of cardiovascular disease (CVD),” wrote first author David A. Watkins, MD, MPH, an associate professor with the University of Washington in Seattle, and colleagues. “Antihypertensives, statins, and antiplatelet drugs are part of the frontline health worker’s basic toolkit, but data from many countries at all levels of income indicate that their use is low.”
Watkins et al. explored the potential of using polypills to combat CVD on a global level. The polypills featured in their analysis included a statin and one or more antihypertension drugs. Some polypills also contained aspirin, but others did not.
The group modeled the impact of distributing polypills from 2023 to 2050, while keeping a close eye on six primary CVD outcomes: death from ischemic heart disease, death from ischemic stroke, death from hemorrhagic stroke, nonfatal acute coronary syndrome, nonfatal stroke and nonfatal new-onset heart failure.
This analysis examined two potential SPC implementation scenarios. One targeted patients who are already enrolled in care, but are not on optimal medical therapy. Another scenario targeted those same individuals while also including individuals who know they face certain risks, but are not enrolled in any level of care.
Overall, the authors estimated that their more conservative approach to polypill implementation could prevent up to 29 million deaths from CVD, and up to 51 million cases of CVD. The more aggressive approach, however, was linked to preventing up to 72 million deaths from CVD, and up to 130 million cases of CVD.
The group also examined “potential harms” of these approaches, including the fact that dizziness and nonfatal gastrointestinal bleeding may be more likely for patients taking certain polypills. Other potential side effects—renal disease and peptic ulcer disease, for instance—have not been seen in significantly higher rates among patients given polypills.
“Since the 1990s, CVD has been responsible for more deaths worldwide than any other type of disease,” the authors wrote. “Without urgent action, population growth and aging, along with unfavorable trends in risk factors, will continue to drive up CVD rates, putting pressure on overstretched and underfunded health systems. SPC-based approaches, including population-based programs, could simplify CVD prevention and accelerate the uptake of evidence-based care, saving many millions of lives.”
Click here to read the full analysis.
Michael has more than 19 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.